



Cadila Healthcare Limited Investor Presentation

October 2014



Well integrated pharma player with global footprints

>60 years

Operational
experience

\$ 1 bn +

Global Revenues

~ 7% of sales

Spent on R&D annually

20+ mfg. sites

Producing >14
bn pills annually

>20% CAGR

In Net Worth and Net
Profits
(FY '09 – FY '14)

1st Indian Company

To discover & develop
an NCE in-house :
Lipaglyn (Saroglitazar)

16,000+ employees

Across the globe,
with 1100+ for R&D

~ 20% CAGR

In Sales
(FY '09 – FY '14)

20 Biosimilars

In pipeline, including 3
novel biologics

Among top 5

Pharmaceutical
Companies in India

15 brands

Among top 300
brands in India

1070+ patents

Filed globally


8th largest

Generic co. in US in
terms of prescriptions


\$ 4 bn +

Market Cap

History of achieving milestones consistently



Key businesses for our journey Beyond the Billion



India formulations

Aspirations

- Maintain strong leadership position in key areas – CVS, GI, respiratory, female healthcare, dermatological.
- Continue to be one of the significant contributors to revenues and profits

Strengths to be leveraged

- One of the largest market players with leading positions in key therapy areas
- Gained 2 positions in dermatological segment – from 6th last year to 4th rank
- Strong brand equity : 15 brands among top 300 in India
- New product launches : 19 during Apr-Jun 14 (incl. line extensions), with 6 First-in-India
- Launched Lipaglyn (Saroglitazar) in Q2 FY 14, the first NCE discovered and developed indigenously by an Indian Pharma company

Market size*	: Rs. 790 bn+
Market growth*	: 7%
Zydus size**	: Rs. 34.1 bn+
Market Share*	: 4.3%
Zydus growth**	: 10%

A first for the nation



* All market related information sourced from AWACS MAT Aug-14

** Zydus numbers including Biochem as reported by AWACS MAT Aug-14

US formulations


Market size* : ~\$ 50 bn
Market growth* : 10%+
Zydus size** : ~ \$ 366 mn
Zydus growth** : 32%

Aspirations

- Be amongst the top 10 generic cos. in US with continued strong focus on customer needs
- One of the significant contributors to revenues and profits

33%+ CAGR in Sales (Last 5 years)

Gross Sales (USD mn)



Strengths to be leveraged

- Ranked 8th (from 10th in last year) among US generic companies based on scripts (Source : IMS).
- 'Preferred supplier' for our customers - received 'Service Level Excellence' award from a large US whole-seller for highly efficient service levels
- Robust regulatory pipeline
 - Increasing focus on complex and niche products
 - Dosage forms - oral solids, injectables, nasals, topicals, transdermals.
 - 225+ ANDA fillings, 85+ approvals so far
 - 60+ launches so far (incl. AGs).

* Approx. numbers as per IMS Report

** Zydus numbers includes that of Neshor and Hercon, as reported in books, for FY 2013-14

Brazil

Market size* : ~ \$ 18 bn
Market growth* : 12-14%
Zydus size** : Rs. 2,353 mn
Zydus growth** : -1%



Aspirations

- To establish strong base with aggressive product launches

Strengths to be leveraged

- Presence in branded generics and generic generics segments with a continued focus on brand building initiatives
- Local manufacturing site
- Robust product pipeline from India – 100+ filings, 40 approvals
- Focused segments (Branded) – female healthcare, hepatology, CNS, CVS and Nutraceuticals
- Product launches : 20+ branded, 15+ generic generics

* Approx. numbers as per IMS Report

** Zydus numbers as reported in books for FY 2013-14

Mexico

Market size* : ~ US\$ 10 bn
Market growth* : 2-3%
Zydus size** : Rs. 109 mn



Aspirations

- To establish strong base with aggressive product launches.

Strengths to be leveraged

- Focused segments (Branded) – CNS, metabolic disorders and respiratory
- Building product pipeline from India – 35+ filings and 15+ approvals so far.
- Commenced commercial operations in June 2013 with the launch of first product in the market from India
- Launched 12 products in the market so far

• Approx. numbers as per IMS Report

** Zydus numbers as reported in books for FY 2013-14

Other Global Markets

Aspirations : To be amongst the leading players in these generics markets

EU

Mkt. Size* : ~\$ 6.5 bn
(France + Spain Gx)
Mkt. Gr. : 2-3%
Zydus Size **: **Rs. 3,902 mn**
Zydus Gr. : 6%

- 8th largest in France, among top 20 in Spain
- Expansion through new products : launched 115+ molecules in France and 80+ molecules in Spain so far (incl. several 'Day 1')
- Leveraging India cost advantage : 175+ new products and 65+ site transfer filings so far, >40% of sales supplied from India

Emerging Mkts.

Mkt. Size* : ~\$ 13 bn
Mkt. Gr. : 12-13%
Zydus Size **: **Rs. 3,592 mn**
Zydus Gr. : 15%

- Operations in different markets of Asia Pacific and Africa with leadership positions in several of these markets
- Consolidated the Branded Generic business in the key markets of Asia Pacific, Africa and Middle East
- Increased product development activities supported by strong regulatory teams

* Approx. numbers as per GERS Report for Europe and as per EvaluatePharma for emerging markets

** Zydus numbers as reported in books for FY 2013-14

Other Businesses


Wellness



Zydus Size **:

Rs. 4,296 mn

Zydus Gr. : 5%



Aspirations : To create niches in wellness space through innovation

- Leadership in sugar substitutes (~93% market share) and peel-off and scrub range for skin-care in India
- Continuous thrust on new product launches with launch of several products under EverYuth brand and launch of low priced Nutralite yummy.
- Recently completed significant re-organization of sales and distribution model in order to ensure continued growth in future.

Animal Health

Zydus Size **:

Rs. 2,754 mn

(incl. Bremer)

Zydus Gr. : 17%

Aspirations : To be a comprehensive, global animal healthcare provider

- One of India's leading animal healthcare co with wide range of drugs, feed supplements and vaccines for livestock, companion animals and poultry
- Presence in key markets across Europe, South America, Asia and Africa through Bremer Pharma, Germany

APIs



Zydus Size **:

Rs. 3,497 mn

Zydus Gr. : 13%

Aspirations : To be a 'reliable' service provider to customers

- Backward integration capabilities to meet captive API requirements
- Operations in India, US and select markets of Europe, Latin America, Asia Pacific and Middle East regions
- Continuous endeavour to improve service levels by improving cost competitiveness and continuous process improvement

Joint Ventures and Alliances

Aspirations : Value creation through win-win alliances and be a partner of choice

Zydus Takeda JV

- State-of-the-art mfg. facility for APIs of Nycomed
- Commissioned the expanded facility to manufacture complex high-end APIs
- Commenced mfg. and supply of 10 products so far (incl. 4 for validation)

Zydus Hospira JV

- State-of-the-art cytotoxic facility approved by leading authorities like MHRA, USFDA, TGA, Health Canada
- Commercial supplies commenced for :
 - EU (6 products) and US (4 products)
 - Expanded scope of collaboration to cover additional products

Bayer Zydus JV

- Operates in female healthcare, metabolic disorders, diagnostic imaging, CVS, diabetes and oncology segments in India
- Leveraging strengths of Bayer's optimised product portfolio and Zydus' marketing and distribution capabilities
- JV scope covers launch of innovator products of Bayer

Out-licensing deal with Abbott

- Licensed 30+ products for ~18 key emerging markets
- Commenced commercial supply of products under the deal and shipped 8 products so far.



Biosimilars and Vaccines

Aspirations : Leverage technological edge to unlock substantial value and create pillars for future growth.

Strengths to be leveraged

Biosimilars

- Dedicated facilities for R&D and mfg.
- 170+ experienced scientists
- Strong pipeline: 17 biosimilars and 3 novel products
- Strong IP position either through own patent or non-infringing processes

Vaccines

- Dedicated facilities for R&D and mfg.
- 60+ experienced scientists
- 10 vaccines under different stages of development

Biosimilar pipeline

Product	Indication	Cloning	Process Devp.	Pre-Clinical Devp.	Regulatory Permission	Clinical Devp.	Mktg. Authorisation
G-CSF	Oncology	LAUNCHED (in India)					
Peg G-CSF	Oncology						
IFN α -2b	Infectious diseases						
Peg IFN α -2b	Infectious diseases						
EPO	Oncology/Nephrology						
Teriparatide	Osteoporosis						
IFN β 1b	Multiple Sclerosis						
Prod 1	Nephrology						
Prod 2	Rheumatoid Arthritis						
MAB 1	Oncology/RA						
MAB 2	Inflammation						
MAB 3	Oncology						
MAB 4	Oncology						
Prod 3	AMI						
Prod 4	Fertility						
Prod 5	Fertility						
Prod 6	Fertility						
MAB 5	Rabies						
PEG-EPO	Nephrology						
Prod 7	Oncology						

NCE research

Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020

Key strengths

- State-of-the art research facility
- Capability of target identification to pre-clinical research / early clinical development
- 300+ scientists dedicated for NME research

NCE Pipeline

Project	Target	Indication	Drug Discovery	Lead optimisation	Pre-clinical Development	IND	Phase I	Phase II	Phase III	NDA
Saro-glitazar	PPAR- α , γ	Dyslipidemia	First glitazar to be approved in the world. Launched in India as "LIPAGLYN"							
Saro-glitazar	PPAR- α , γ	Lipodystrophy								
Saro-glitazar	PPAR- α , γ	Non-alcoholic Steatohepatitis								
ZYH7	PPAR- α	Dyslipidemia								
ZYG19	GPR 119 Agonist	Diabetes								
ZYDPLA1	DPP-IV inhibitor	Diabetes								



World class infrastructure to support growth journey

Formulations Mfg.



Oral Solids (India)

- Ahmedabad (USFDA)
- Baddi (USFDA)
- Goa
- Sikkim
- Ahmedabad SEZ (onco. and others)
- Daman (Biochem)

Oral Solids (outside India)

- US (Nesher Pharma – controlled substances)
- Brazil
- Germany (animal health)

Other dosage forms (India)

- Transdermals – Ahmedabad SEZ
- Topicals – Ahmedabad
- Vaccines Mfg. - Ahmedabad

API Mfg.



- Ankleshwar (USFDA)
- Dabhasa (USFDA)
- Oncology API, Ahmedabad (USFDA)
- Biologics active substances and MABs, Ahmedabad

Mfg. facilities for partners



- Cytotoxic Injectable for Hospira JV – Ahmedabad SEZ (USFDA)
- API facility for Nycomed JV - Mumbai
- Cytotoxic Injectable for BSV JV – Ahmedabad SEZ

Product Development



- Formulations Development, Ahmedabad (400+ scientists)
- API Process Research, Dabhasa (200+ scientists)
- Biosimilars and Vaccine Research, Ahmedabad (200+ scientists)

Pillars of Organisational Health

Continuous endeavour to improve overall organisation health in four key areas



Creating value and developing talent across the organisation

Enhancing bottom-up innovation across the organisation


Promoting collaboration across businesses and functions

Strengthening accountability by proper performance management

Key Financial Numbers – FY 2013-14

Consolidated (Rs. Mio.)	Amount	Gr.%
Total Income from Operations	72,240	13.6%
EBIDT	12,002	6.7%
EBIDT % to Income from Ops.	16.6%	
Profit before tax ¹	9,594	18.6%
PBT % to Income from Ops.	13.3%	
Net Profit ¹	8,189	25.3%
Net Profit % to Income from Ops.	11.3%	
Debt net of cash (31-Mar-14)	21,516	
Capex (FY 2013-14)	4,660	

Segment-wise Gross Sales



**Other Markets,
33% of total,
Up 5% y-o-y**

**Home Markets,
67% of total,
Up 20% y-o-y**

¹ Excludes exceptional items.

Thank You.



Safe Harbour Statement

This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements . The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.

www.zyduscadila.com